U.S. stock night market volatility: Palatin Tech rose 5.04% in the night session, with active capital inflow attracting market attention

U.S. Stock Market After-Hours Movements Palatin Tech rose 5.04% in after-hours trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Recursion Pharmaceuticals rose 2.88% in after-hours trading, with a trading volume of $463,900, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Moderna rose 0.25% in after-hours trading. Based on recent key news: On November 21, Moderna announced a debt financing plan to enhance financial flexibility. This move aims to support the company's future financial goals, although the stock price fell 3.47% after a market reversal. Source: Benzinga On November 24, changes in U.S. vaccine policy affected Moderna's market performance. Kennedy's policy led to a decline in vaccination rates, prompting Moderna to increase lobbying expenditures to cope with market pressure. Source: Zhitong Finance On November 21, analysts maintained a cautious stance on Moderna, keeping a hold rating. Despite the company's efforts to improve its financial situation, the overall outlook remains complex. Source: MarketBeat. The impact of changes in vaccine market policy is significant. Precision Science fell 2.87% in after-hours trading. Based on recent key news: On November 21, Abbott Laboratories announced the acquisition of Precision Science for $21 billion, with a transaction price of $105 per share. This news initially boosted Precision Science's stock price, but it later fell due to market concerns about post-acquisition integration. Source: Abbott Laboratories announcement On November 21, the target price for Precision Science was raised to $105 by several institutions, reflecting market recognition of its acquisition price. However, with the stock price approaching the acquisition price, further upside potential is limited. Source: Analyst reports from Barclays, Citigroup, etc. On November 22, Precision Science executives sold common stock, raising market concerns about insiders' confidence in the company's future, leading to pressure on the stock price. Source: EDGAR system disclosure. The cancer diagnostics market is growing rapidly, with significant capital inflow